Pharmaceutical evidence highlights concerns for industry after Brexit

05 December 2017

The Business, Energy and Industrial Strategy Committee publishes written evidence for its Brexit inquiry on the pharmaceutical industry.

Written evidence published

The submissions have been published ahead of a public evidence session on Tuesday when the Committee will be questioning witnesses from the pharmaceutical industry, including the Association of the British Pharmaceutical Industry (APBI) and Janssen Pharmaceutical, on the impact of Brexit.
The Committee has received written evidence submissions (19 in total) from the following: American Pharmaceutical Group, Association of British Healthcare Industries, AstraZeneca, British Generic Manufacturers Association (BGMA), British Medical Association, British Specialist Nutrition Association, Department for Business, Energy and Industrial Strategy, GMB, Johnson & Johnson, Lilly UK, Merck, MSD, PAGB, Roche, STOPAIDS, The Association of the British Pharmaceutical Industry and the Bio-Industry Association, The Royal Society, Union of Shop, Distributive and Allied Workers (Usdaw), and Unite the Union.

Serious concerns about future regulation

Rachel Reeves MP, Chair of the Business, Energy and Industrial Strategy Committee, said:

"The evidence we have received suggests the impact of Brexit on the cost of medicines, investment in the UK and access to new and innovative research and products may be threatened by Brexit.

There are serious concerns raised around the future regulation of pharmaceuticals, mutual recognition of medicines, and the prospect of damaging disruption to cross-EU drug supply chains.

This is very concerning, with uncertainty risking the UK becoming a less desirable place for investment and development in a growing, productive industry.

We are keen to examine the detail of these concerns and to hear from the industry what it wants from the Government to ensure the smoothest possible transition as we leave the EU."

Customs and trading arrangements

The written evidence submissions are published ahead of the BEIS Committee public evidence session at 10am on Tuesday which is likely to examine the impact Brexit on the pharmaceutical industry, in terms of regulation, research and development and access to highly-skilled workforces.
The evidence session on Tuesday will consider how different scenarios relating to future customs and trading arrangements might affect the industry in the UK and consider what the Government should be seeking to achieve in negotiations.  

Witnesses include the Association of the British Pharmaceutical Industry, British Generic Manufacturers Association, PAGB, Janssen Pharmaceutical and other pharmaceutical companies.


Tuesday 5 December 2017, Committee Room 6, Palace of Westminster

At 9.45am

At 10.45am

  • Mark Hicken, Managing Director UK & Ireland for Janssen, Pharmaceutical Companies of Johnson and Johnson
  • Peter Ballard. Managing Director, Xiromed

Further information

 Image: PA

More news on: Parliament, government and politics, Parliament, European Union, Health services and medicine, Medicine, Business, industry and consumers, House of Commons news, Commons news, Committee news, Exiting the European Union

Share this page